Citius OncologyCTOR -6.07%10 Days Inventory is 6,281.97 as of Mar. 2026. GuruFocus rates CTOR with a GF Score™ of 10/100. The stock has 2 warning signs investors should review. Among 919 Drug Manufacturers companies, Citius Oncology ranks worse than 99.89% on this metric.
The historical rank and industry rank for Citius Oncology's Days Inventory or its related term are showing as below:
CTOR'
s Days Inventory Range Over the Past 10 Years
Min: 0 Med: 0 Max: 6538.27
Current: 6538.27
During the past 4 years, Citius Oncology's highest Days Inventory was 6538.27. The lowest was 0.00. And the median was 0.00.
CTOR's Days Inventory is ranked worse than 99.89% of 919
companies
in the Drug Manufacturers industry
Industry Median: 162.83
vs CTOR: 6538.27
Citius Oncology's Days Inventory
increased
from Mar. 2025 (0.00) to Mar. 2026 (6,281.97).
It might indicate that Citius Oncology's sales slowed down.
Warning Sign:
If a company builds up inventory, it may mean it is having difficulties selling its goods.
Inventory Turnover measures how fast the company turns over its inventory within a year.
Citius Oncology's Inventory Turnover for the
three
months ended in Mar. 2026 was 0.01.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Citius Oncology's Inventory-to-Revenue for the
three
months ended in Mar. 2026 was 13.59.
Citius Oncology (NAS:CTOR) Days Inventory Explanation
Days Inventory indicates the liquidity of the inventory. Generally, a lower Days Inventory is preferred as it indicates a shorter duration to clear off the inventory. An increase of the ratio may indicate the company's sales slowed. Similar ratios related to Days Inventory are:
1. Inventory Turnover measures how fast the company turns over its inventory within a year.
Citius Oncology's Inventory Turnover for the
three
months ended in Mar. 2026 is calculated as
2. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Citius Oncology's Inventory to Revenue for the
three
months ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
A lot of business are seasonable. It makes more sense to compare Days Inventory from the same period in the previous year instead of from the previous quarter.
Citius Oncology Days Inventory Related Terms
Citius Oncology Days Inventory Historical Data
* Premium members only.
The historical data trend for Citius Oncology's Days Inventory can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CTOR vs INCR, BGM, CPIX: Days Inventory Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Citius Oncology's Days Inventory, along with its competitors' market caps and Days Inventory data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Citius Oncology Days Inventory vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Citius Oncology's Days Inventory distribution charts can be found below:
* The bar in red indicates where Citius Oncology's Days Inventory falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Citius Oncology (CTOR) has a Days Inventory of 6,281.97 as of Mar. 2026. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on Citius Oncology and its competitors. According to the industry distribution chart, Citius Oncology ranks #918 out of 919 companies in the Drug Manufacturers industry, placing it in the top 99.9%.
Is Citius Oncology's Days Inventory too high?
Citius Oncology's current Days Inventory is 6,281.97. The Drug Manufacturers industry median Days Inventory is 162.83. Citius Oncology's value of 6,281.97 is 3758% above this industry median. Based on the distribution chart, Citius Oncology ranks #918 out of 919 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Citius Oncology has a GF Score™ of 10/100, reflecting its overall financial health beyond just this single metric.
How does Citius Oncology's Days Inventory compare to INCR and BGM?
According to the Drug Manufacturers industry distribution chart, Citius Oncology ranks #918 out of 919 companies for Days Inventory. This places Citius Oncology in the lower half of its industry. The industry median Days Inventory is 162.83. Citius Oncology's value of 6,281.97 is 3758% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Inventory for a Drug Manufacturers company?
The median Days Inventory among Drug Manufacturers companies is 162.83, based on 919 companies in the industry. Companies in the top quartile (top 25%) have a Days Inventory significantly above this median, while those in the bottom quartile fall well below. However, Days Inventory should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Citius Oncology's current Days Inventory of 6,281.97 is 3758% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Inventory mean?
A high Days Inventory can signal that a stock is expensive relative to its fundamentals. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on Citius Oncology and its competitors. For the Drug Manufacturers industry, the median Days Inventory is 162.83 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Citius Oncology's current Days Inventory is 6,281.97. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Citius Oncology stock overvalued right now?
Citius Oncology (CTOR) has a current Days Inventory of 6,281.97. The current Days Inventory is 6,281.97 and 3758% above the Drug Manufacturers industry median of 162.83. Citius Oncology's overall GF Score™ is 10/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Inventory calculated?
Days Inventory is calculated from a company's financial statements. For Citius Oncology (CTOR), the current Days Inventory is 6,281.97 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Citius Oncology Inc is a biopharmaceutical company focused on developing and commercializing targeted oncology therapies.The Company centers on achieving a market position by advancing therapies with reduced development and clinical risks, and competitive advantages supported by intellectual property and regulatory exclusivity protection. This includes new formulations of previously approved drugs with substantial existing safety and efficacy data or expanded indications for approved therapies. The company focused on key geographies and stakeholders, majorly on cancer centers and patients.
10GF Score
Get the complete analysis for CTOR
Days Inventory is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CTOR has been successfully added to your 
